Colorectal Cancer Clinical Trials in Cincinnati, Ohio

8 studies are recruiting for colorectal cancer in Cincinnati, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

   Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine and tipiracil) plus …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Oncology Hematology Care - Blue Ash /ID# 280143, Cincinnati, Ohio

   Locations

   73 in total

   Run by

   AbbVie

   See if you can join NCT07525206 on ClinicalTrials.gov

2. A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

   This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor [CAR] T), in adult participants with advanced gastrointestinal (GI) cancers. The study will consist of 2 p…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati Cancer Center, Cincinnati, Ohio

   Locations

   5 in total

   Run by

   Dispatch Biotherapeutics

   See if you can join NCT07544589 on ClinicalTrials.gov

3. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

   The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati (UC) - Cancer Institute, Cincinnati, Ohio

   Locations

   52 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06586515 on ClinicalTrials.gov

4. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

   TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

   Stage

   Phase 2

   Ages

   18 to 130

   Site

   Research Site, Cincinnati, Ohio

   Locations

   96 in total

   Run by

   AstraZeneca

   See if you can join NCT05489211 on ClinicalTrials.gov

5. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

   The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati Medical Center, Cincinnati, Ohio

   Locations

   32 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06445062 on ClinicalTrials.gov

6. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

   This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati Cancer Center, Cincinnati, Ohio

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT03947385 on ClinicalTrials.gov

7. 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

   This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patient…

   Stage

   Phase 1

   Ages

   15 and older

   Site

   Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

   Locations

   5 in total

   Run by

   Lantheus Medical Imaging

   See if you can join NCT06298916 on ClinicalTrials.gov

8. Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

   The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

   Stage

   Not phased

   Ages

   18 and older

   Site

   TriHealth Cancer Institute, Cincinnati, Ohio

   Locations

   20 in total

   Run by

   Tempus AI

   See if you can join NCT05234177 on ClinicalTrials.gov